Glycemic Control and Osteohealth in Adults Living with Type 1 Diabetes

Last updated: February 24, 2025
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Overall Status: Active - Recruiting

Phase

N/A

Condition

Diabetes Prevention

Diabetes And Hypertension

Diabetes Mellitus Types I And Ii

Treatment

AID

Clinical Study ID

NCT06158503
MP-02-2024-11708
  • Ages 18-100
  • All Genders

Study Summary

Bone damage is frequently observed in type 1 diabetes, and hyperglycemia is associated with an increased risk of fracture. This pilot study in 25 people living with type 1 diabetes aims to determine whether the introduction of an automated insulin delivery (AID) system improves bone markers through rapide optimization of glycemic control. Measurements will be taken before the start of AID, 2 months and 4 months afterwards.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years;

  • Diagnosis of T1D or latent autoimmune diabetes of adults (LADA) for at least oneyear;

  • Current HbA1c >8.0% and high glycemic variability (CV >36.0% using CGM);

  • Participant planning to start using one of the commercially available AID;

  • Anticipated use of the closed-loop mode;

  • Willing to share CGM data during the study period.

Exclusion

Exclusion Criteria:

  • Woman who was pregnant, gave birth or breastfed less than 6 months before thebeginning of the study or who plans to become pregnant during the study;

  • Conditions affecting bone turnover markers, such as chronic kidney disease (estimated GFR <30 ml/min), liver disease, intestinal malabsorption including celiacdisease, organ transplant, active cancer, rheumatoid arthritis, and endocrinopathies (active hyperthyroidism, uncontrolled hypothyroidism with abnormal TSH, parathyroiddisease, hypogonadism, Cushing syndrome, adrenal insufficiency and acromegaly);

  • Anticipated therapeutic change and/or type of CGM sensor, insulin pump, or AIDduring the study period;

  • Anticipated need to use acetaminophen during the study period at a dose above 1gevery 6 hours;

  • Current or anticipated use of hydroxyurea;

  • Intake in the past 12 months of drugs influencing bone turnover markers, such asoral or intra-articular glucocorticoids (≥ 7.5 mg daily Prednisone or equivalentduring ≥ 3 months or ≥ four intra-articular glucocorticoid infiltrations in the pastyear), aromatase inhibitor therapy for breast cancer and anti-androgen therapy forprostate cancer, anticoagulants, SGLT-2 inhibitors, thiazolidinediones, andanti-osteoporosis drugs;

  • Unable to consent.

Study Design

Total Participants: 25
Treatment Group(s): 1
Primary Treatment: AID
Phase:
Study Start date:
February 01, 2025
Estimated Completion Date:
June 30, 2027

Study Description

Background: Bone damage is a frequently overlooked complication of type 1 diabetes (T1D), but significantly increases the risk of fractures as early as childhood. Fractures in individuals with T1D increase the risk of delayed healing, postoperative complications, loss of autonomy, reduced quality of life and even mortality. The pathophysiology of bone alterations in T1D probably differs from that of primary osteoporosis. Studies show lower bone mineral density in T1D, but this is not sufficient to fully explain the risk of fractures. T1D is also characterized by low bone remodeling and altered bone microarchitecture. Although chronic hyperglycemia is a risk factor for fracture in T1DM, the effect of improved glycemic control on bone markers remains unclear. The main hypothesis is that rapid optimization of the glycemic profile (hyperglycemia and variability) may improve bone remodeling in people living with T1DM who have suboptimal glycemic control.

Aim: The primary objective of this pilot study is to quantify the proportion of participants significantly increasing at least one of the serum markers of bone remodeling post-installation of an automated insulin delivery system.

Secondary objectives are to quantify: 1) the magnitude of change in each of the serum markers of bone remodeling pre-intervention and at 2 and 4 months post-intervention; 2) the efficacy of the automated insulin delivery system in terms of glycemic control and variability (mean change in HbA1c and glycemic parameters derived from the continuous glucose monitoring system).

Methods: method: This is a prospective pilot study involving 25 adults aged 18 and over living with T1DM or latent autoimmune diabetes of adults (LADA) who are interested in starting an automated insulin delivery system (artificial pancreas).

This study will involve 3 visits:

  1. Visit 1: before installation of the automated insulin delivery system,

  2. Visit 2: follow-up at 2 months after installation of the automated insulin delivery system,

  3. Visit 3: follow-up at 4 months after installation of the automated insulin delivery system.

During visits 1 and 3, participants will take a blood sample, perform a brief physical examination and complete questionnaires.

During visit 1, participants will also undertake a urine sample, and the research team will conduct a brief interview to obtain information on their diabetes diagnosis, associated complications, and medication use.

During Visit 2: blood sample only.

The project will not interfere with the participant's diabetes management. They will be asked to share a copy of their 14-day continuous glucose monitoring profile during the visit periods.

Connect with a study center

  • CHUM

    Montréal, Quebec H2X 3E4
    Canada

    Active - Recruiting

  • Centre Hospitalier de l'Université de Montréal

    Montreal,
    Canada

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.